Opposite effects of tamoxifen on metabolic syndrome-induced bladder and prostate alterations: a role for GPR30/GPER? (Q39095837)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037776%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

title

Opposite effects of tamoxifen on metabolic syndrome-induced bladder and prostate alterations: a role for GPR30/GPER? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037776%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037776%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Mauro Gacci

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037776%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

P Comeglio

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037776%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

A Morelli

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037776%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

I Cellai

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037776%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

E Sarchielli

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037776%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

S Filippi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037776%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

E Maneschi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037776%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

F Corcetto

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037776%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

C Corno

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037776%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

G B Vannelli

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037776%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

M Maggi

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037776%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

publication date

26 August 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037776%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037776%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

74

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037776%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

10-28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037776%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037776%20AND%20SRC:MED&resulttype=core&format=json

Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract

21 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Lower urinary tract symptoms, obesity and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Benign prostate hyperplasia: a review of the year's progress from bench to clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Lower urinary tract symptoms, benign prostatic hyperplasia, and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Lifestyle factors, benign prostatic hyperplasia, and lower urinary tract symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Association of hypertension with symptoms of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Lower urinary tract symptoms in relation to lifestyle and medical conditions in Japanese workers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

The prevalence and correlates of urinary tract symptoms in Norwegian men: the HUNT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Birth weight, abdominal obesity and the risk of lower urinary tract symptoms in a population based study of Swedish men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Relationship of lifestyle and clinical factors to lower urinary tract symptoms: results from Boston Area Community Health survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Metabolic syndrome and lower urinary tract symptoms: the role of inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Lower urinary tract symptoms and its potential relation with late-onset hypogonadism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Testosterone deficiency, insulin resistance and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Testosterone and metabolic syndrome: a meta-analysis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Testosterone, cardiovascular disease and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

21 January 2018

Testosterone deficiency

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Long‐term results of high‐power holmium laser vaporization (ablation) of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Serum sex hormones and measures of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Association between lower urinary tract symptoms and serum levels of sex hormones in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Associations between longitudinal changes in serum estrogen, testosterone, and bioavailable testosterone and changes in benign urologic outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Testosterone replacement therapy by testosterone ointment relieves lower urinary tract symptoms in late onset hypogonadism patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Development of diabesity in mice with neuronal deletion of Shp2 tyrosine phosphatase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Sex-hormone-induced inflammation and fibromuscular proliferation in the rat lateral prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Expression of proinflammatory genes during estrogen-induced inflammation of the rat prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Androgens and estrogens in benign prostatic hyperplasia: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Sex steroid receptors in male human bladder: expression and biological function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Estrogen Receptor Null Mice: What Have We Learned and Where Will They Lead Us?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Estrogen in the adult male reproductive tract: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Impact of androgen/estrogen ratio: lessons learned from the aromatase over-expression mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Estrogen signaling through the transmembrane G protein-coupled receptor GPR30.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Testosterone/estradiol ratio regulates NO-induced bladder relaxation and responsiveness to PDE5 inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Estradiol activates group I and II metabotropic glutamate receptor signaling, leading to opposing influences on cAMP response element-binding protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

A transmembrane intracellular estrogen receptor mediates rapid cell signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Characterization and functional role of androgen-dependent PDE5 activity in the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Acute vardenafil administration improves bladder oxygenation in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Progestin receptors: isoforms and antihormone action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Chronic inflammation in the pathogenesis of benign prostatic hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Estrogen receptors: therapies targeted to receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Estrogen receptor beta acts as a dominant regulator of estrogen signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Oestrogen and benign prostatic hyperplasia: effects on stromal cell proliferation and local formation from androgen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Localization of estrogen and androgen receptors in male reproductive tissues of mice and rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Perinatal exposure to estrogenic compounds and the subsequent effects on the prostate of the adult rat: evaluation of inflammation in the ventral and lateral lobes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22723

21 January 2018

Identifiers

DOI

10.1002/PROS.22723

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037776%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24037776%20AND%20SRC:MED&resulttype=core&format=json